Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 13:12:1759720X20964031.
doi: 10.1177/1759720X20964031. eCollection 2020.

The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases

Cosimo Bruni  1 , Stefano Gentileschi  2 , Giovanni Pacini  3 , Caterina Baldi  2 , Marco Capassoni  3 , Lorenzo Tofani  3 , Marco Bardelli  2 , Laura Cometi  3 , Luca Cantarini  2 , Francesca Nacci  3 , Michele Vietri  4 , Francesca Bartoli  5 , Ginevra Fiori  5 , Bruno Frediani  2 , Marco Matucci-Cerinic  3
Affiliations

The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases

Cosimo Bruni et al. Ther Adv Musculoskelet Dis. .

Abstract

Aims: Switching from originator to biosimilar is part of current practice in inflammatory rheumatic musculoskeletal diseases (iRMDs) such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondylarthritis (axSpA), with evidences derived from both etanercept (ETN) to SB4-switching randomized controlled trials and real-life registries. We investigated the safety and treatment persistence of ETN/SB4 in a multi-iRMD cohort derived from two rheumatology departments in our region.

Methods: Adult patients with iRMDs, treated with ETN for at least 6 months and switched to SB4 in stable clinical condition, were eligible for this retrospective evaluation. Retrospective data on adverse events, loss of efficacy and persistence on treatment were collected until latest available follow-up.

Results: A total of 220 patients (85 RA, 81 PsA, 33 axSpA, 14 juvenile idiopathic arthritis and seven other conditions; 142 females, mean age 58 ± 7 years, disease duration 12 ± 4 years, ETN duration 7 ± 4 years) were enrolled, with median follow-up of 12.1 (9.7-15.8) months. A total of 50 patients (22.7%) presented with at least one adverse event, with 36 (16.4%) disease flares and 30 (13.6%: 11 for safety and 19 loss of efficacy) SB4 withdrawals. Cumulative SB4 treatment persistence was 99.1%, 88.6% and 64.6% at 6, 12 and 18 months respectively. Back-switch to ETN was performed in 17/30 cases, the remaining cases were managed with change of biologic disease modifying or conventional synthetic anti-rheumatic drug. Age was the only significant predictor of SB4 interruption at 6 months.

Conclusion: Our real-life data confirm the safety profile of switching from ETN to SB4, with slightly higher treatment persistence rates compared with other real-life registries.

Keywords: SB4; etanercept; persistence; rheumatic diseases; safety; switch.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: LuC reports advisory board honoraria with Biogen. MMC reports speaker’s and advisory board honoraria from Biogen Italia. All other authors declare no conflict of interest with the scientific content of the manuscript.

Figures

Figure 1.
Figure 1.
Flow-chart of treatment outcome in the study population. AE, adverse event; bDMARD, biologic disease modifying anti-rheumatic drug; ETN, etanercept.
Figure 2.
Figure 2.
Survival curve of persistence on treatment with SB4.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. Epub ahead of print 22 January 2020. DOI: 10.1136/annrheumdis-2019-216655. - DOI - PubMed
    1. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016; 75: 499–510. - PubMed
    1. Ward MM, Deodhar A, Gensler LS, et al. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis research and treatment network recommendations for the treatment of Ankylosing Spondylitis and nonradiographic axial Spondyloarthritis. Arthritis Rheumatol 2019; 71: 1599–1613. - PMC - PubMed
    1. Monaco C, Nanchahal J, Taylor P, et al. Anti-TNF therapy: past, present and future. Int Immunol 2015; 27: 55–62. - PMC - PubMed
    1. European Medicines Agency. Enbrel, summary of product characteristics, www.ema.europa.eu/en/documents/product-information/enbrel-epar-product-i... (2019, accessed 12 March 2020).